Valuation: Egetis Therapeutics AB

Market Cap 3.23B 340M 292M 272M 250M 469M 32.58B 478M 1.26B 16.33B 1.28B 1.25B 54.05B P/E 2026 *
66.3x
P/E 2027 * -17.7x
Enterprise Value 2.68B 282M 242M 225M 207M 389M 27.01B 396M 1.04B 13.54B 1.06B 1.04B 44.81B EV / Sales 2026 *
6.15x
EV / Sales 2027 * 8.77x
Free-Float
40.16%
Yield 2026 *
-
Yield 2027 * -
1 day-3.03%
1 week-6.08%
Current month+13.33%
1 month+6.75%
3 months+1.49%
6 months+42.56%
Current year+27.34%
1 week 6.73
Extreme 6.73
7.28
1 month 5.86
Extreme 5.86
7.35
Current year 4.23
Extreme 4.23
7.35
1 year 3.62
Extreme 3.625
7.35
3 years 3.02
Extreme 3.025
9.3
5 years 3
Extreme 3.005
9.3
10 years 3
Extreme 3.005
50.75
Manager TitleAgeSince
Chief Executive Officer 50 2017-06-15
Director of Finance/CFO 47 2017-12-30
Chief Tech/Sci/R&D Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 65 2016-12-31
Director/Board Member 65 2016-12-31
Chairman 61 2024-05-05
Date Insider Type Main position Quantity % Market Cap.
5/13/26 Sell

Chief Executive Officer

-286,071 0.0724%
5/11/26 Fiscal year

Chief Financial Officer

264,880 0.0670%
1/16/26 Buy

Chairman

150,000 0.0380%
Change 5-day change 1-year change 3-year change Capi.($)
-2.02%-6.08%+27.10%+64.25% 341M
+2.38%+5.57%+86.02%+115.89% 72.21B
+0.87%+17.34%+57.17%+94.08% 63.98B
-3.60%-0.20%-2.60%+473.09% 28.53B
+3.63%+8.62%+66.69%+23.95% 25.07B
-2.14%+20.54%-0.23%-5.52% 28.42B
-0.51%+5.73%+38.71%-14.19% 20.04B
-1.79%-4.51%+241.26%+414.48% 18.19B
+1.81%+0.85%+16.89%+546.06% 15.96B
-0.81%+6.84%+42.82%+153.02% 13.48B
Average -0.33%+4.66%+57.38%+186.51% 28.62B
Weighted average by Cap. +0.44%+7.46%+61.08%+162.06%

Financials

2026 *2027 *
Net sales 435M 45.9M 39.3M 36.67M 33.65M 63.23M 4.39B 64.47M 170M 2.2B 172M 169M 7.29B 328M 34.59M 29.61M 27.63M 25.35M 47.64M 3.31B 48.58M 128M 1.66B 130M 127M 5.49B
Net income 342M 36.06M 30.88M 28.81M 26.43M 49.67M 3.45B 50.65M 133M 1.73B 135M 132M 5.73B -117M -12.34M -10.57M -9.86M -9.05M -17M -1.18B -17.34M -45.6M -592M -46.34M -45.34M -1.96B
Net Debt -552M -58.22M -49.85M -46.51M -42.68M -80.19M -5.57B -81.77M -215M -2.79B -219M -214M -9.24B -353M -37.25M -31.9M -29.76M -27.31M -51.31M -3.56B -52.32M -138M -1.79B -140M -137M -5.91B
Logo Egetis Therapeutics AB
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Employees
44
Date Price Change Volume
26-08-20 SEK 6.800 -2.02% 574,661
26-08-19 SEK 6.940 -1.14% 580,491
26-08-18 SEK 7.020 -0.99% 512,294
26-08-17 SEK 7.090 -0.98% 433,837
26-08-14 SEK 7.160 -1.10% 661,887
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
6.940SEK
Average target price
15.33SEK
Spread / Average Target
+120.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EGTX Stock